Biotechnology

Using tiny micromotors to diagnose and treat disease in the human body could soon be a reality. But keeping these devices intact as they travel through the body remains a hurdle.

A medical device company with a new approach treats eye diseases by stimulating the optic nerve of the cornea with neuromodulation.

Sensor technology is a key piece for a number of applications including robotics, Internet of Things, consumer electronics, smart city/home, smart factory, etc. Sensor innovation is often an important motivation within various industries.

A research team have bioengineered lungs and transplanted them into adult pigs with no medical complication.

New stroke-healing gel helped regrow neurons and blood vessels in mice with stroke-damaged brains, hinting at what may someday be a new therapy for stroke in people.

A simple retinal prosthesis is being developed using cheap and widely-available organic pigments used in printing inks and cosmetics, it consists of tiny pixels like a digital camera sensor on a nanometric scale. Researchers hope that it can restore sight to blind people.

A pilot trial for patients with drug refractory rheumatoid arthritis in the U.S. The multi-center study, "A Randomized Controlled Study of the Safety and Efficacy of Neurostimula- tion Using a Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis," assesses the safety and efficacy of a proprietary bioelectronic device in adult patients with RA who are not adequately responsive to multiple biologic agents.

Tissue engineering, broadly described as the combination of cells, engineering methods and biochemical factors to create living biological tissue, is a fast-growing field that has the potential to significantly accelerate the advancement of medicine.

electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, has announced it completed its Series B financing that has brought in just over $70 million of capital to the company.

As the point-of-care biosensor market is expected to expand to $33 billion by 2027, investing in the right technology and business model now is paramount to success over the next decade.